Tuesday, 3 December 2019

MRG November Publications

Featuring Tolergenic dendritic cells, MRI and rituximab for JIA patients.

Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis.
Spiering R, Jansen MAA, Wood MJ, Fath AA, Eltherington O, Anderson AE, Pratt AG, van Eden W, Isaacs JD, Broere F, Hilkens CMU.
J Transl Med. 2019 Nov 14;17(1):375. doi: 10.1186/s12967-019-2128-4.
PMID: 31727095 [PubMed - in process] Free Article
Similar articles 

Can quantitative MRI be used in the clinical setting to quantify the impact of intra-articular glucocorticoid injection on synovial disease activity in juvenile idiopathic arthritis?
Bennett JL, Wood A, Smith N, Mistry R, Allen K, Jandial S, Tuckett JD, Gowdy SC, Foster HE, McErlane F, Hollingsworth KG.
Pediatr Rheumatol Online J. 2019 Nov 21;17(1):74. doi: 10.1186/s12969-019-0377-7.
PMID: 31752877 [PubMed - in process] Free PMC Article
Similar articles 

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, De Cock D, Foster HE, Southwood TR, Thomson W, Hyrich KL.
Rheumatology (Oxford). 2019 Feb 1;58(2):331-335. doi: 10.1093/rheumatology/key306.
PMID: 30358861 [PubMed - indexed for MEDLINE] Free PMC Article
Similar articles

Wednesday, 30 October 2019

Sjogrens Syndrome in the News

See https://www.ncl.ac.uk/press/articles/latest/2019/10/sjogrensyndromebreakthrough/

Wednesday, 16 October 2019

Synovial Fibroblasts


Faculty Seminar



Kirsten Klein

Centre of Experimental Rheumatology, University Hospital Zurich







Thursday 17th October 2019



11.30 – 12.30


Kirsten will present:


"Epigenetics of synovial fibroblasts"


Synovial fibroblasts are the most abundant stromal cells in joints that promote inflammation and drive joint destruction in rheumatoid arthritis. Synovial fibroblasts from different joint localizations exhibit profound differences in their expression profiles, which translate into a joint specific enrichment of arthritis relevant pathways, molecules and functional differences. Epigenetic factors act as intermediaries to link genetic and environmental risk factors to altered gene expression levels in a cell type-specific manner. Epigenetic mechanisms define the positional identity of synovial fibroblasts and underlie their role in persistent inflammation. Interfering with epigenetic modifications and their related epigenetic enzymes have therapeutic potential in rheumatoid arthritis.



Professor John Isaacs








Friday, 11 October 2019

PSORT Showcase - 18th November 2019, Royal College of Physicians, London

The PSORT (Psoriasis Stratification to Optimise Relevant Therapy) Stratified Medicine Consortium will host a one day Showcase event at the Royal College of Physicians, London to highlight its progress, achievements and plans for the future.

Formed by dermatologists, industry partners (including pharmaceutical companies), the British Association of Dermatologists and importantly, the Psoriasis Association, PSORT was established to determine whether it could predict which patients with psoriasis would respond best to a particular biologic drug. This, rather than the existing system of "trial and error" prescribing, would allow new treatment plans to be devised that would be personalised to the individual with psoriasis.  If successful, such stratification might also achieve cost savings to the NHS and aid the pharmaceutical industry in the development of new drugs for psoriasis.

The Showcase will focus on how the key aspects of our programme have worked together for patient benefit. It will feature invited lectures by leading international speakers (academic, clinical, industry) interspersed amongst updates from scientists and clinicians from the PSORT team. These will be supplemented by a lunchtime poster exhibition. The day concludes with a networking wine reception.

The Showcase is free to attend and is open to the research community, industry, founders and patients alike.

Join us as we discuss how our findings might be of relevance to you. 

To register, please use the BAD registration link  https://www.eventsforce.net/bad/277/home



Friday, 27 September 2019

What Can Patients Tell Us About Sjӧgren's Syndrome?

Apparently, they can tell us quite a lot. 

Three international cohorts, two clinical trials including patient reported symptoms, clinical and  biological data, proteomics and transcriptomics. 

See the latest paper in The Lancet Rheumatology.